ArticleAmerican heart journal plus : cardiology research and practice2024
Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations.
Article in American heart journal plus : cardiology research and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Association of Lp(a) with coronary plaque burden and high-risk plaque features: A meta-analysis of imaging studies.Atherosclerosis · 2026Pooled it
- Expert consensus on Lipoprotein(a) in the Gulf countries: Navigating cardiovascular risk and therapeutic advances.Atherosclerosis plus · 2026Article
- What is your next step? A case of a composite dyslipidemia with atherosclerotic trajectory: bridging primary care to internal medicine setting.Internal and emergency medicine · 2026Article
- Selected Emerging Biomarkers in Type 2 Diabetes Mellitus: Clinical Insights and Implications for Precision Care.Medicina (Kaunas, Lithuania) · 2026Review
- Identifying barriers to lipoprotein(a) testing in secondary cardiovascular prevention and co-designing implementation strategies: an Italian behavior change wheel-informed study.Frontiers in cardiovascular medicine · 2026Article
- Ethnic Variation in Lipoprotein(a) Levels in the Kazakhstan Population.Journal of clinical medicine · 2025Article
- Cardiovascular Implications of Lipoprotein(a) and its Genetic Variants: A Critical Review From the Middle East.JACC. Asia · 2025Review
- A Critical Appraisal of Lipid Management in the Post-Statin Era: Comparison on Guidelines, Therapeutic Targets, and Screening in a Case-Based Framework of Lipid Management.JACC. Advances · 2025Article
- Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study.American journal of preventive cardiology · 2025Article
- Comments: "Association between lipoprotein(a) and coronary heart disease risk in type 2 diabetes mellitus and evaluation of statin treatment effects".Revista da Associacao Medica Brasileira (1992) · 2025Article
- Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice.Journal of clinical lipidologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated lipoprotein(a) (Lp[a]) is an independent, genetic risk factor for atherosclerotic cardiovascular disease (ASCVD) that impacts ~1.4 billion people globally. Generally, Lp(a) levels remain stable over time; thus, most individuals need only undergo Lp(a) testing through a non-fasting blood draw once in their lifetime, unless elevated Lp(a) is identified. Despite the convenience of the test for clinicians and patients, routine Lp(a) testing has not been widely adopted. This review provides a guide to the benefits of Lp(a) testing and solutions for overcoming common barriers in practice, including access to testing and lack of awareness. Lp(a) testing provides the opportunity to reclassify ASCVD risk and drive intensive cardiovascular risk factor management in individuals with elevated Lp(a), and to identify patients potentially less likely to respond to statins. Moreover, cascade screening can help to identify elevated Lp(a) in relatives of individuals with a personal or family history of premature ASCVD. Overall, given the profound impact of elevated Lp(a) on cardiovascular risk, Lp(a) testing should be an essential component of risk assessment by primary and specialty care providers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.